Trulicity EMA vs FDA Approach: How Two Agencies Evaluated the Same Drug Differently

How FDA Approved Dulaglutide

The FDA granted approval to dulaglutide on September 18, 2014, under NDA 125469, on the basis of the AWARD (Assessment of Weekly AdministRation of dulaglutide) phase 3 program. The initial indication was glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise. No cardiovascular outcome trial data were required for initial approval, consistent with the 2008 FDA guidance on CV risk in antidiabetic drugs.

The AWARD Trial Program and Initial Benefit-Risk Assessment

The AWARD program included eight randomized controlled trials comparing dulaglutide against placebo, metformin, sitagliptin, exenatide twice daily, insulin glargine, and insulin lispro. AWARD-1 (N=976) demonstrated a placebo-adjusted HbA1c reduction of 1.51 percentage points at 26 weeks with the 1.5 mg dose [1]. The FDA's initial label required a black-box warning for medullary thyroid carcinoma (MTC) risk, derived from rodent carcinogenicity studies, consistent with the class-wide GLP-1 receptor agonist warning applied to exenatide and liraglutide [2].

The agency did not mandate a Risk Evaluation and Mitigation Strategy (REMS) for dulaglutide, judging the existing MTC warning language, contraindication in patients with personal or family history of MTC, and the available prescriber education to be sufficient for safe use [3].

FDA Label Expansion After REWIND (2020)

The REWIND cardiovascular outcomes trial (N=9,901; median follow-up 5.4 years) published in The Lancet in 2019 showed that dulaglutide 1.5 mg once weekly reduced the primary composite endpoint of nonfatal myocardial infarction, nonfatal stroke, or death from cardiovascular causes by 12% compared with placebo (HR 0.88; 95% CI 0.79 to 0.99; P=0.026) [4]. In May 2020, the FDA updated the Trulicity label to add an indication for reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors [3].

REWIND was notable for enrolling a population with a relatively low baseline cardiovascular event rate: 69% of participants had only cardiovascular risk factors rather than established disease, and mean baseline HbA1c was 7.2%, lower than most other GLP-1 CVOT populations [4]. The FDA's willingness to grant a broad CV indication covering the risk-factor-only subgroup distinguished the Trulicity label from the more restricted labeling applied to some competitor agents.

Dose Escalation Pathway on the FDA Label

The FDA-approved dosing sequence begins at 0.75 mg once weekly. After four weeks, the prescriber may increase to 1.5 mg. The 2020 label update added 3 mg and 4.5 mg doses for additional glycemic benefit, based on data from the AWARD-11 trial (N=1,842), where the 4.5 mg dose produced an HbA1c reduction of 2.02 percentage points versus 1.53 percentage points for 1.5 mg at 36 weeks [5].

How the EMA Evaluated Dulaglutide

The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for dulaglutide in October 2014, leading to European Commission approval in November 2014 under the brand name Trulicity. The European Public Assessment Report (EPAR) document number EMEA/H/C/002825 details the agency's benefit-risk conclusions.

Summary of Product Characteristics vs. FDA Prescribing Information

The EMA issues a Summary of Product Characteristics (SmPC) rather than a Prescribing Information (PI) document. The two documents share the same core clinical data but differ structurally and in some specific content areas.

The SmPC places the MTC rodent carcinogenicity data in Section 5.3 (preclinical safety) with a contraindication in Section 4.3 for patients with MTC or Multiple Endocrine Neoplasia syndrome type 2, mirroring the FDA black-box language in substance but presenting it without the typographically distinct boxed format used in U.S. Labeling [6]. European prescribers therefore receive the same clinical warning in a different visual hierarchy, which some pharmacovigilance researchers argue affects prescriber attention to contraindications.

The EMA SmPC also differs in its handling of pancreatitis. The FDA label presents acute pancreatitis as a warning with instruction to discontinue if suspected. The EMA SmPC lists pancreatitis under Section 4.4 (special warnings) and includes a slightly more detailed clinical description of the diagnostic criteria the prescriber should apply before attributing pancreatitis to dulaglutide specifically, given background rates of the condition in type 2 diabetes patients [6].

REWIND and the EMA CV Label Update

The EMA reviewed REWIND data and updated the Trulicity SmPC to reflect cardiovascular benefit, but the specific wording differs from the FDA's U.S. Label. The European SmPC states that dulaglutide reduces the risk of cardiovascular events and references the REWIND population characteristics, including the mixed primary-prevention and secondary-prevention enrollment. The EMA's updated label language is somewhat more hedged regarding the primary-prevention subgroup compared with the FDA's definitive indication statement, reflecting the EMA's tendency to stay closer to the trial population description rather than extrapolating to a broader indicated population [7].

Post-Market Surveillance: EMA Pharmacovigilance vs. FDA Sentinel

Both agencies require ongoing safety monitoring, but their operational frameworks differ substantially.

The EMA uses the Periodic Safety Update Report (PSUR) system, under which Eli Lilly must submit cumulative safety data on a defined schedule. The CHMP's Pharmacovigilance Risk Assessment Committee (PRAC) reviews PSURs and can issue label modifications, communications to healthcare professionals, or signal assessments. The EMA also integrates spontaneous adverse event reports from member-state national competent authorities into the EudraVigilance database [8].

The FDA monitors Trulicity through two parallel channels. First, the standard MedWatch spontaneous reporting system collects adverse event data from patients and providers [3]. Second, the FDA Sentinel System, a distributed active surveillance network covering more than 500 million patient-years of electronic health data, can conduct rapid queries on specific safety signals without requiring data to leave source health systems [9]. The Sentinel System's scale gives the FDA a structured-data advantage in detecting rare adverse events at a population level, which the EMA's EudraVigilance system partially addresses through its own signal detection analytics.

Key Label Differences: A Side-by-Side View

Understanding the specific divergences between the FDA Prescribing Information and the EMA SmPC helps prescribers and formulary managers interpret trial data and safety signals correctly.

Thyroid Cancer Warning Format

Both agencies require a thyroid carcinoma warning, but the FDA uses a boxed warning format that sits above the full prescribing information text. The SmPC distributes the same clinical content across multiple sections without a box. A 2021 analysis in the British Journal of Clinical Pharmacology examined whether formatting differences in GLP-1 class warnings affected prescriber recall and found measurable differences in recall rates between the two formats, though the clinical significance of that difference for patient outcomes has not been quantified [10].

Pancreatitis Language

The FDA label for Trulicity states: "Based on spontaneous postmarketing reports, acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists" [3]. The EMA SmPC provides similar content but adds guidance on differential diagnosis, noting that elevated amylase and lipase levels are common in type 2 diabetes patients independently of GLP-1 therapy, a nuance absent from the FDA's more concise warning text.

Renal Dosing Guidance

Neither agency requires dose adjustment for renal impairment, as pharmacokinetic studies showed no clinically meaningful change in dulaglutide exposure across renal function categories. Both labels advise caution in patients with severe renal impairment due to limited clinical trial data, but neither specifies a modified dosing schedule [3][6]. This represents one area of substantive agreement between the two regulatory documents.

Pediatric Indication Status

As of early 2025, the FDA has not approved dulaglutide for pediatric use, and the label contains a pediatric use section noting that safety and efficacy in patients under 18 years old have not been established [3]. The EMA SmPC similarly restricts the indication to adults [6].

REWIND Trial: The Data Behind the CV Indication

REWIND (Researching Cardiovascular Events with a Weekly Incretin in Diabetes) is the study that changed dulaglutide's regulatory profile on both sides of the Atlantic.

Trial Design

REWIND enrolled 9,901 adults with type 2 diabetes aged 50 years or older across 371 sites in 24 countries. Participants were randomized to dulaglutide 1.5 mg once weekly or placebo, added to existing therapy. Median follow-up was 5.4 years. The primary endpoint was a three-point major adverse cardiovascular event composite: nonfatal MI, nonfatal stroke, or CV death [4].

Efficacy Results

Dulaglutide reduced the primary composite endpoint with an HR of 0.88 (95% CI 0.79 to 0.99; P=0.026). Nonfatal stroke drove a substantial share of the benefit, with an HR of 0.76 (95% CI 0.61 to 0.95). All-cause mortality was not significantly different between arms (HR 0.90; 95% CI 0.80 to 1.01; P=0.067) [4].

The FDA cited the stroke reduction finding explicitly in the label update rationale, noting that the stroke benefit was consistent across the mixed primary-prevention and secondary-prevention population. The EMA's PRAC review similarly highlighted the stroke data but was more cautious in the SmPC wording about the primary-prevention subgroup given the pre-specified analysis structure.

Safety Signals Identified in REWIND

Gastrointestinal adverse events occurred more frequently with dulaglutide than placebo. Nausea affected 19.7% of the dulaglutide group versus 11.2% of placebo; diarrhea affected 16.7% versus 10.6% [4]. Serious pancreatitis rates did not differ significantly between arms, which both agencies used to contextualize the class-wide pancreatitis warning [4].

What the Regulatory Differences Mean for Prescribers

The table below summarizes the practical decision points where the FDA and EMA frameworks diverge. Clinicians working within U.S. Health systems use the FDA Prescribing Information; those in EU member states use the SmPC. Clinicians reviewing global trial data may encounter both documents.

FDA vs. EMA Dulaglutide Label Comparison

| Feature | FDA (Prescribing Information) | EMA (SmPC) | |---|---|---| | Approval date | September 18, 2014 | November 2014 | | MTC warning format | Black-box warning | Section 4.3 contraindication + Section 5.3 preclinical | | CV indication | Explicit indication statement (2020) | SmPC text updated post-REWIND; more population-descriptive | | Pancreatitis guidance | Warning with discontinuation instruction | Warning with differential diagnosis context | | Renal dosing | No adjustment required; caution in severe impairment | Same | | Pediatric use | Not established (<18 years) | Not established | | Post-market surveillance | MedWatch + FDA Sentinel | EudraVigilance + PSUR/PRAC | | Highest approved dose | 4.5 mg once weekly | 4.5 mg once weekly |

A U.S. Prescriber seeing a patient with type 2 diabetes and two or more CV risk factors but no established CVD can use the FDA's current Trulicity indication as explicit label support for dulaglutide selection. A prescriber in an EU member state should review the SmPC language carefully, as the EMA's cardiovascular indication wording is more tied to the REWIND trial population description than to a broadly stated risk-factor indication.

The FDA's Sentinel System provides U.S. Prescribers and payers a data infrastructure for ongoing real-world safety monitoring that has no exact European counterpart. When the FDA issues a safety communication about Trulicity based on Sentinel data, that signal may not appear simultaneously in EMA communications, creating a brief but real information asymmetry for global formulary teams.

Guidance on Medullary Thyroid Carcinoma Risk

Both labels contraindicate dulaglutide in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2. The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm notes that the MTC risk from rodent studies has not been confirmed in humans, but advises that the contraindication be observed until human long-term registry data are available [11]. The FDA has required Eli Lilly to maintain a pregnancy exposure registry and monitor for thyroid cancer cases through a 15-year registry, details of which are referenced in the Prescribing Information [3].

Patient Counseling Points Shared Across Both Labels

Despite their differences, the FDA PI and EMA SmPC align on the core patient counseling points: teach patients to recognize and report symptoms of pancreatitis (persistent severe abdominal pain), instruct on hypoglycemia risk when dulaglutide is combined with insulin or a sulfonylurea, and advise on the importance of adequate hydration given nausea-related fluid intake reduction [3][6].

Post-Market Safety Record: What Real-World Data Show

The post-market safety record for dulaglutide through both the FDA's MedWatch system and the EMA's EudraVigilance database has been broadly consistent with the AWARD trial program and REWIND trial adverse event profiles. No new class-defining safety signal has prompted a label revision beyond the CV indication update and the 2020 dose escalation addition.

Thyroid Cancer Registry Data

The 15-year thyroid cancer registry mandated by the FDA enrolled patients between 2015 and 2023. Interim analyses have not identified a human signal for MTC attributable to dulaglutide, consistent with the mechanistic understanding that GLP-1 receptors are present on rodent but not human thyroid C-cells at meaningful density [12]. The EMA's PRAC has reviewed this registry data in PSURs without issuing additional label modifications specific to thyroid cancer risk as of early 2025.

Cardiovascular Safety in Non-Trial Populations

Real-world evidence from large U.S. Claims and electronic health record databases, reviewed under the FDA Sentinel framework, has generally supported the CV benefit signal seen in REWIND, though observational data cannot establish causality. A 2022 analysis published in Diabetes Care examined dulaglutide users versus dipeptidyl peptidase-4 inhibitor users in a U.S. Administrative claims database and found a lower rate of hospitalization for heart failure with dulaglutide, an endpoint not part of REWIND's primary analysis [13].

Gastrointestinal Adverse Events in Practice

Post-market pharmacovigilance data from both EudraVigilance and MedWatch indicate that nausea, vomiting, and diarrhea remain the most frequently reported adverse effects, consistent with REWIND's 19.7% nausea rate in the active arm [4]. Reports of gastroparesis have increased with broader GLP-1 class use across agents; the FDA is monitoring dulaglutide-specific rates through Sentinel, and the EMA has issued a class-level signal assessment note for GLP-1 receptor agonists and delayed gastric emptying [8].

Trulicity FDA Approval Timeline at a Glance

• September 18, 2014: FDA approves NDA 125469 for glycemic control in type 2 diabetes.
• 2017: FDA approves a pre-filled pen device update and additional AWARD trial data incorporation.
• July 2020: FDA approves the CV indication based on REWIND, adding doses of 3 mg and 4.5 mg based on AWARD-11.
• 2022 onward: FDA Sentinel queries assess real-world gastroparesis and thyroid cancer signals; no label changes issued as of early 2025.

The EMA's timeline follows a similar arc with the November 2014 initial approval, SmPC updates post-REWIND, and ongoing PSUR review cycles.